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Mission of the Annual Postdoctoral Science Symposium
The Annual Postdoctoral Science Symposium (APSS) was initiated on August 4, 2011, by the MD
Anderson Postdoctoral Association to provide a platform for talented postdoctoral fellows throughout the
Texas Medical Center to present their work to a wider audience.
APSS is a scientific symposium organized by postdoctoral fellows from The University of Texas MD
Anderson Cancer Center that welcomes submissions and presentations from postdoctoral fellows from all
Texas Medical Center affiliated institutions and other Houston area institutions. The APSS provides a
professional venue for postdoctoral scientists to develop, clarify and refine their research as result of formal
reviews and critiques by faculty and other postdoctoral scientists. Additionally, attendees discuss research
on a broad range of subjects, engage in professional development sessions, create academic connections and
develop new collaborations.
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Competition Winners
Nearly 50 abstracts were submitted for the 10th APSS, wherein 12 of the submitting postdoctoral fellows
were selected for oral presentations in applied science, basic science, and clinical/translational research.

Oral Competition – First-Place Winners
Applied Science: “Identifying predictors of opioid misuse in adult trauma patients
using a Bayesian data science approach”

Constanza de Dios, Ph.D.

Mentor: Joy M. Schmitz, Ph.D.

Basic Science: “Elucidating the role of purinergic signaling during rotavirus
infection”

Kristen A. Engevik, Ph.D.

Mentor: Joseph M. Hyser, Ph.D.

Clinical/Translational Research: “Dual inhibition of glutamine metabolism and
oxidative phosphorylation (OxPhos) constitutes a novel approach to target metabolic
reprogramming in NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL)”
Natalia Baran, M.D.

Mentor: Marina Konopleva M.D., Ph.D.
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Poster Competition Winners
Shared first position:
“Clinical implication of co-occurring molecular alterations in patients with Philadelphia chromosomepositive B-cell acute lymphoblastic leukemia treated with hyper-CVAD plus dasatinib or ponatinib”
Yuya Sasaki, M.D., Ph.D.

Mentors: Koichi Takahashi, M.D., Ph.D.
Elias Jabbour, M.D.

“Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response”
Melanie Winkle, Ph.D.

Mentor: George A. Calin, M.D., Ph.D.

Shared second position:
“The oral poliovirus vaccine restricts rotavirus vaccine replication and infection”
Julia Hankins, Ph.D.

Mentor: Sasirekha Ramani, Ph.D.

“Brain reactivity and attentional bias to drug cues in cocaine users”
Heather E. Soder, Ph.D.

Mentor: Francesco Versace, Ph.D.
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Oral Presentations
The following categories were included for oral presentations: Applied Science, Basic Research and
Clinical-Translational Science. Each category included up to four presenters, all of whom were required to
be first authors of their submitted abstracts.

Only abstracts of presenters who agreed to have their abstracts published are included.
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Applied Science
Gold nanorod hydrogel for laser-induced HIPEC in gastric cancer
Karem A. Court1, Hangjin Yu1, Diana Chan1, Elvin Blanco2, Arturas Ziemys2, Ashley Holder3
1Department

of Surgery, Houston Methodist Research Institute, Houston, TX; 2Department of

Nanomedicine, Houston Methodist Research Institute, Houston, TX; 3Department of Surgery, University of
Alabama at Birmingham, Birmingham, AL.
Background: Cancers that spread to or originate in the peritoneum are termed peritoneal malignancies.
These cancers are often deemed unresectable and have limited treatment options, as chemotherapy
administered intravascularly has little effect and surgical resection may miss microscopic disease. The
standard of care is surgical removal of visible tumor followed by infusion of heated chemotherapy into the
abdominal cavity (HIPEC). The existing approach has substantial risk of local recurrence and toxicity to
intra-abdominal organs. Gold nanorods (GNR) can be stimulated by near-infrared (NIR) laser radiation to
generate heat in a controlled and predictable manner. The goal of this study was to develop an innovative
hydrogel film to produce controlled, mild hyperthermia and provide local delivery of chemotherapy to
peritoneal malignancies.
Methods: Film was designed with gelatin and glycerol, and its properties were assessed. Cisplatin (CPT)
and mitomycin C (MMC) were encapsulated in film; loading and release were measured. GNR
concentration was determined to achieve 42 ⁰C using NIR laser. Human gastric cancer cells (SNU-16) were
treated with CPT or MMC film to determine IC50. Cells were treated with combinations of film with GNR,
chemotherapy and NIR laser to determine cytotoxicity. Intraperitoneal biodistribution was assessed in a
murine model of gastric cancer with peritoneal metastases (SNU-16) using Cy5-GNR, with fluorescence
measured by IVIS.
Results: A gelatin film had 90% transparency, had Young’s modulus of 685 MPa at 28 ⁰C and 594 MPa at
37 ⁰C, and was soluble in water-based solution at 37 ⁰C. Chemotherapy was successfully loaded with 80%
efficiency and released from film, between 2 and 4 hours. The GNR film reached 42 ⁰C in 30 seconds when
exposed to NIR laser. IC50 for CPT was 81.4±9.9 μM and for MMC was 0.20±0.04 μM. Treatment of SNU16 with NIR laser and GNR-chemo film to 42 ⁰C resulted in similar efficacy to soluble treatment.
Preliminary biodistribution results in vivo demonstrated that GNR-film at 4 hours after implantation
accumulates on the peritoneal surface and metastases.
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Conclusions: To date, no study has evaluated nanoparticle platforms for HIPEC. Preclinical evidence of
efficacy utilizing a hydrogel GNR-chemotherapy film could lead to clinical trials in peritoneal malignancies.
If successful, treatment of other cancers could benefit from this film to decrease the incidence of local
recurrence and chemotherapy toxic effects.
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Identifying predictors of opioid misuse in adult trauma patients using a Bayesian data science
approach
Constanza de Dios1, Robert Suchting1, Heather E. Soder1, Jin H. Yoon1, Danielle Kessler2, Shweta Kapoor1,
Angela L. Stotts3, Angela M. Heads1, John A. Harvin4, Charles E. Green1, Scott D. Lane1, Joy M. Schmitz1
1

Faillace Department of Psychiatry and Behavioral Sciences, UTHealth McGovern Medical School, The

University of Texas Health Science Center at Houston, Houston TX; 2Department of Psychological
Sciences, Rice University, Houston TX; 3Department of Family and Community Medicine, UTHealth
McGovern Medical School, The University of Texas Health Science Center at Houston, Houston TX;
4

Center for Translational Injury Research, Department of Surgery, University of Texas Health Science

Center at Houston, Houston TX.
Background: Although the use of prescription opioids can alleviate acute pain, it can lead to opioid misuse,
a growing public health concern. One population of interest is recent trauma and surgery patients.
Identifying variables in existing in-patient assessments can be useful for informing interventions for opioid
dependence after discharge. Data science approaches can fulfill the aim of identifying pertinent variables.
Methods: Data were collected from adult patients (N=635) from a Level 1 trauma center in Houston, TX.
Thirty-nine items from the Multimodal Analgesic Strategies for Trauma (MAST) database, 13 items from
National Trauma Data Standard, and two hospital measurements (morphine milligram equivalents/day and
numeric pain rating scale) were used as predictors. The primary outcome was high (19.5% of patients) or
low (79.8% of patients) risk level of opioid use, measured at baseline using the Opioid Risk Tool.
Generalized linear modeling with Bayesian inference was used to quantify the probability that the effect of
each predictor on risk level was greater or less than zero, given the data and weakly informative priors. Risk
level was modeled via a binomial distribution with a weakly informative horseshoe prior.
Results: Predictors of risk level in the sample were: younger age; higher numerical pain ratings; prior opioid
use; the presence of amphetamines, barbiturates, cocaine, phencyclidine, or THC in the urine drug screen;
and being a smoker (posterior probabilities > 75%). The majority of sizable-effect predictors were from the
MAST database.
Conclusions: The present research demonstrates the utility of Bayesian data science methods in indicating
pertinent measures for predicting risk of opioid misuse in trauma and surgery patients. The findings also
support the utility of existing in-hospital assessments for informing interventions appropriate to level of risk.
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Examining lung cancer screening: a review of challenges and opportunities in publicly available data
Kristin G. Maki1, Robert J. Volk1 and Sanjay S. Shete2
1

Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston

TX; 2Department of Biostatistics and Epidemiology, The University of Texas MD Anderson Cancer Center,
Houston, TX.
Background: Screening for lung cancer with low-dose computed tomography (LDCT) is recommended for
high-risk individuals meeting specific eligibility criteria. Current guidelines suggest that eligible adults with
a heavy smoking history will benefit from periodic LDCT, but due to several associated risks (e.g., false
positives, radiation exposure, overdiagnosis), a shared decision-making consultation is required for
reimbursement by the Centers for Medicare and Medicaid Services (CMS) and recommended but not
required by the United States Preventive Services Task Force (USPSTF) guidelines. Large-scale, national
data sets provide a wealth of information about health-related behaviors to inform cancer control efforts at a
population level as well as important information regarding uptake of and adherence to recommended
preventive behaviors, including cancer screening. However, due to varying methods and survey-level
factors, there are challenges related to their use.
Methods: We examined characteristics, intended uses, and variables related to lung cancer screening (LCS)
from 4 population-based surveys: 1) National Health Interview Survey (NHIS), 2) Behavioral Risk Factor
Surveillance System (BRFSS), 3) National Health and Nutrition Examination Survey (NHANES), and 4)
Health Information National Trends Survey (HINTS). The most recent information pertaining to LCS was
then compared with the current CMS and USPSTF guidelines. It must be noted that the surveys are not
always consistent over time; the BRFSS includes cancer modules that states may opt to use, and other
surveys update their questions over time and do not always include the same items from year to year. An
overview of 33 publications using these sources is also provided.
Results: None of the data sets included items that fully assess current LCS guidelines for CMS
reimbursement. The 2015 NHIS dataset allows analysis of LCS uptake in concordance with USPSTF
guidelines.
Conclusions: This examination of NHIS, BRFSS, NHANES, and HINTS identified three key challenges
across the surveys. First, the surveys provide varied pieces of information relating to LCS uptake, screening
adherence (this is difficult in these cross-sectional surveys with reliance on self-reported data), and patientprovider communication. Second, the majority of the surveys (NHANES excluded) are cross-sectional and
rely on self-report (excluding the physical examination portion of NHANES) and may include some level of
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bias. Third, the sample size for LCS-eligible individuals may be a small subsample of the population. This
may result in difficulties for researchers in adjusting for bias.
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Feasibility of an automated radiation treatment planning system for cost-effective cancer therapy in
low- and middle-income countries
Kyuhak Oh1, 2, Bishwambhar Sengupta2, Carlos Cardenas1, Laurence Court1, Eric Ford2
1

Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston TX;

2

Department of Radiation Oncology, The University of Washington, Seattle, WA.

Background: The global burden of cancer is on the rise, especially the cases in low-and middle-income
countries (LMICs) are increasing rapidly. By 2035, the annual number of cancer cases is projected to reach
up to 25 million, and 70% of cases are expected to occur in LMICs where there are severe shortages in
radiotherapy resources. Our group is developing a cost-effective system for intensity-modulated radiation
therapy (IMRT) based on Cobalt-60. However, individual computerized treatment plans are required for
each patient. This study explores the tools necessary for automated treatment planning, which may help
mitigate these limitations by reducing the planning burden and staff workload, increasing the quality and
efficiency of radiation plan creation.
Methods: This novel IMRT technology consists of a Cobalt-60 source and a ring-shaped design of the
radiation-compensator system made by a 3D printer and filled with mm sized tungsten beads. For this study,
the widely-used Eclipse Treatment Planning System was commissioned using measured data of the Cobalt60 beam. A linear accelerator machine was used because the IMRT optimization module is not supported
for the Cobalt-60 machine. An IMRT treatment plan using compensators were created. A custom python
script was used, which creates a unique compensator based on a fluence map extracted from the IMRT
optimization module in the Eclipse. A Monte Carlo (MC) program was used for verification. The effects of
tungsten beads were studied, the commissioned beams were validated, and the treatment plan was created.
Results: Radiation profiles and transmission of the beads-based compensator agreed with those of solid tin,
and it appeared that the reusable tungsten bead was a feasible alternative to the solid compensator. Percent
depth dose curves and profiles of Eclipse and MC simulations were investigated and had agreements with
differences under 2% and 4%, respectively. Two simple treatment plans for 4 or 5 fields were designed for
both the Eclipse and the MC. The resulting doses were consistent for both cases.
Conclusions: Cobalt-60 beam was commissioned in Eclipse planning software, and IMRT plans based on
the Cobalt-60 unit combined with reusable compensator materials were created, demonstrating the
feasibility of this approach. The results from this cost-effective feasible delivery system meet the current
needs for LMICs. This study is still developing, and in upcoming studies the treatment planning system may
17

be validated in clinical trials and combined with the Radiation Planning Assistant system under
development by our group.
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Basic Science
Acute myeloid leukemia expands osteoprogenitor-rich niche in the bone marrow and alters bone
homeostasis
Anudishi Tyagi1, Bin Yuan1, Stanley Ly1, Fouad El-Dana1, Vinitha Kuruvilla1, Qi Zhang1, Christine
Peterson2, Xin Zhou3, Benoit deCrombrugghe3, Michael Andreeff1, Marina Konopleva1, Behrang Amini4,
V. Lokesh Battula1,5
1

Section of Molecular Hematology and Therapy, Department of Leukemia; 2Department of Biostatistics;

3

Department of Genetics; 4Departmentof Musculoskeletal Imaging; 5Department of Breast Medical

Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: Stromal cells in the bone marrow (BM) microenvironment have been shown to contribute to
leukemogenesis. We have reported that acute myeloid leukemia (AML) cells induce osteogenic
differentiation in mesenchymal stromal cells (MSCs) in the BM to facilitate AML progression in mice.
However, the effect of AML cells on various osteo-lineage cells in the BM microenvironment is not known.
Here we hypothesized that AML cells alter bone marrow niche by expanding osteoprogenitor cells as well
as remodeling the bone.
Methods: We generated triple-transgenic mice by crossing Osx-CreERt2-mice with Ocn-GFP;ROSAtdTomato-mice. The resulting triple-transgenic mice had the genotype of Osx-CreERt2;Ocn-GFP;ROSAtdTomato and were used to determine the effects of AML cells on specific subsets of osteoblast lineage. We
used AML patient-derived xenograft (PDX) models and bone density data from computer tomography (CT)
imaging in AML patients to determine the effect of AML cells on bone density and volume.
Results: In transgenic mice implanted with syngeneic AML cells, we found a 3- to 4-fold increase in
Osterix+ cells, but not Osteocalcin+ cells, suggesting that AML cells expand osteoprogenitor cells during
short-term exposure. Further, to investigate the effects of AML on bone during long-term exposure, we
implanted AML-PDX cells (total 10 models) into NSG mice and analyzed femurs by micro-CT and
histological analysis. Interestingly, we observed a dramatic increase in cortical bone thickness and new
medullary bone formation in ~50% of the PDX models tested. We also found that increase in the bone
volume is associated with less aggressive PDX models (which take 4-5 months to reach 90% peripheral
blood [PB] engraftment). Aggressive PDX models (which take only 4-8 weeks to reach 90% PB
engraftment) did not develop new bone. To validate this finding we performed Masson-Goldner's trichrome
staining and observed web-like trabecular bone formation in mice with less aggressive PDX models, which
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was not observed in aggressive AML PDX models. Interestingly, we also observed massive bone resorption
associated with osteoclast activation in some PDX models, suggesting high bone turnover in AML bones.
Next, we measured bone densities in AML patients and cancer-free individuals by chest CT imaging. We
found that bone densities were significantly higher in most AML patients (~70%) compared to healthy
individuals and high bone density was associated with good patient outcomes.
Conclusion: Our data suggest that AML cells induce supportive osteoprogenitor-rich niche in the BM. High
bone turnover in AML bones suggests altered bone homeostasis in AML patients.
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Identifying mechanisms of immune evasion in microsatellite instable endometrial cancers
Brenda Melendez1, Emily Hinchcliff1, Nisha Gokul1, Daniel McGrail1, Elizabeth Whitley1, Russell R.
Broaddus2, Rosemarie E. Schmandt3, Karen H. Lu1, Melinda S. Yates1
1

Departement of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD

Anderson Cancer Center, Houston, TX; 2Department of Pathology and Laboratory Medicine, UNC School
of Medicine, Chapel Hill, NC; 3The University of Texas Health Science Center at Houston, Houston, TX.
Background: Inherited or sporadic defects in mismatch repair genes (MLH1, MSH2, MSH6, and PSM2)
can lead to microsatellite instable (MSI) tumors—most commonly colon, endometrial, or gastric tumors.
High mutation rates in MSI tumors have been associated with greater immunogenicity, but these tumors can
evade immune response. Recently developed mouse models of MSI endometrial cancer (EC) were used to
evaluate immune surveillance mechanisms.
Methods: Uterine-targeted MSH2 knockout (PRCre+MSH2flox/flox) mice were characterized, and it was
determined that 22% of mice develop spontaneous EC by 12+ months. MSI was evaluated by PCR. Immune
infiltration and function were analyzed by immunohistochemistry and digital spatial profiling. Tumors were
divided into TILHIGH and TILLOW (<10 TIL/mm2) groups based on CD8a. Transcriptome analysis of tumor
and normal controls was performed. A subset of transcripts was validated by RT-PCR. Cell lines were
generated from spontaneous tumors and used for orthotopic syngeneic tumor studies and immune
characterization. A gene signature score approach was used to quantify immune-related expression changes
by functional categories for tumors from PRCre+MSH2flox/flox mice and MSI EC patient data from TCGA.
Results: Tumors were MSI and included endometrioid, serous, and mixed histologies. Tumors showed
varying degrees of CD8+ T cell infiltration, irrespective of histology. Of 7 tumors, 4 were TILHIGH and 3
were TILLOW. TILHIGH tumors had increased infiltration of dendritic cells suggestive of increased antigen
presentation. Type I interferon (IFN) response was upregulated, including genes IFI203 (FC=18.5), IFI204
(FC=11.1), and T cell chemoattractant CXCL9 (FC=5.7). There was no difference in type II IFN response.
TILLOW tumors had low or negligible expression of IFN-associated genes. In conjunction with increases in
immunogenicity, TILHIGH tumors exhibited increased immune exhaustion markers, TIM3 (FC=2.4) and
LAG3 (FC=3.2). Tumoral PD-L1 expression was negative (<1% of positive cells). Cell lines from TILHIGH
and TILLOW tumors used in vivo retained the immune profile of the original tumor. Similar to our mouse
model, TILHIGH MSI EC patients from TCGA also showed activation of type I IFN, increased dendritic cell
infiltration, and increased exhaustion markers.
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Conclusion: The PRCre+MSH2flox/flox mouse model reflects the spectrum of immunogenicity observed in
clinical studies. TILHIGH tumors express type I IFN-associated factors involved in immunity, while also upregulating negative immune regulatory molecules. TILLOW tumors lack key mediators needed for robust
immune activation. Generated cell lines will be essential to test the efficacy of immunotherapies, in both
immunogenic and non-immunogenic MSI tumors, and to study mechanisms of resistance to treatment.
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Generating an immunogenic, protective elephant endotheliotropic herpesvirus (EEHV) vaccine
Jennifer L. Spencer Clinton1, Taylor Pursell2, Jie Tan1, Rongsheng Peng1, and Paul Ling1
1

Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX;

2

Department of Microbiology and Immunology, Stanford University, Stanford, CA.

Background: Endangered Asian elephants are a keystone species facing many threats, including severe
hemorrhagic disease (HD) caused by the elephant endotheliotropic herpesvirus (EEHV). EEHV-HD is the
leading cause of death in captive, juvenile Asian elephants in North America and Europe and also affects
captive and wild elephants in their natural range countries. While EEHV can also cause lethal disease in
captive African elephants, its prevalence remains unknown. Due to the rapid severe onset of EEHV,
detection and treatment options are limited. Thus, our goal is to develop a vaccine that elicits strong
antibody and cell-mediated immunity (CMI) against EEHV to prevent lethal disease.
Methods: Our vaccine approach will include recombinant modified vaccinia virus Ankara (MVA) vectors
expressing key immunoreactive EEHV proteins. Previous studies with EEHV and human herpesviruses
indicate that glycoproteins B, H, and L (gB, gH, and gL) are likely to induce protective humoral immunity
and CMI. MVA expressing gH and gL will be achieved using a novel approach that incudes expression as
self-processing subunits mediated by a picornavirus 2A peptide. Recombinant MVA expressing one or
multiple EEHV antigens will be generated by recombination, subsequent sorting, and plaque purification.
Mice will be injected intraperitoneally with MVA vaccines with homologous or heterologous prime boosts
of each antigen. Vaccine immunogenicity will be assessed by the presence of antigen-specific antibodies
and T cell activation via the luciferase immunoprecipitation assay system and flow cytometry, respectively.
Results: We have successfully generated an MVA recombinant that expresses the EEHV gB glycoprotein
and have initiated cloning of the gH/gL glycoproteins after verifying that the 2A-linked subunits were
processed efficiently. Preclinical studies have shown that MVA-gB vaccinations induce robust anti-gB
antibodies and T cell responses after homologous prime boosts in mice. We also demonstrated that a single
priming vaccine and one boost are sufficient to induce immune responses and are not significantly different
than two subsequent vaccine boosts.
Conclusions: In preliminary studies, we have shown that MVA-gB vaccination can yield significant levels
of antibody production and T cell activation in a mouse model. Future studies will incorporate multi
antigenic MVA recombinants expressing EEHV gH/gL antigens in addition to gB and will compare
heterologous prime boosts with purified antigen subunits and adjuvants. Completion of this study will
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provide insights into EEHV vaccine development to protect elephants against lethal HD, as well as highlight
MVA as an innovative vaccine platform for other herpesvirus infections.
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Elucidating the role of purinergic signaling during rotavirus infection
Kristen A. Engevik1, Alexandra Chang-Graham1, Melinda A. Engevik2, Jacob L. Perry1, Joseph M. Hyser1
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Background: Rotavirus is an enteric virus that causes life-threatening diarrhea in children, resulting in
~128,500 deaths each year. Rotavirus infects a limited number of cells at the tips of the villi in the small
intestine. Yet, rotavirus influences cell types far away from the site of infection. As a result, the accepted
theory in the field is that infected cells signal to uninfected cells through some unknown compound. We
recently identified that infected cells release the signaling molecule ADP, which binds to the P2Y1 receptor
on nearby uninfected cells. This signaling causes intercellular calcium waves that originate from the
infected cell and propagate through uninfected cells. We hypothesized that rotavirus-driven ADP/P2Y1
signaling modulates downstream effectors of infection, such as mucus expulsion, serotonin release, and
chloride secretion. We also speculated that ADP/P2Y1 signaling recruits innate immune cells such as
macrophages and drives local inflammatory responses.
Methods: To test this hypothesis, we generated cell lines and human intestinal enteroids that stably express
cytosolic genetically encoded calcium indicators to characterize calcium signaling throughout rotavirus
infection by time-lapse imaging.
Results: We found that intercellular calcium waves required P2Y1 signaling for prorogation, and inhibition
of other P2Y receptors were not involved. Using human intestinal enteroids, we observed that P2Y1mediated signaling was critical for activation of secretory epithelial cells, including serotonin secretion from
enterochromaffin cells and mucus expulsion from goblet cells. In monkey MA104 cells, rotavirus infection
chemoattracted mouse bone marrow-derived macrophages, which also harbor the P2Y1 receptor. Moreover,
application of ADP to macrophages stimulated secretion of the chemokine MCP-1. These effects were
blunted by pharmacological inhibitors of the P2Y1 receptor. Consistent with our in vitro findings, we
observed that murine rotavirus infection increased serotonin secretion and mucin expulsion and drove
accumulation of macrophages. These effects were minimized in the presence of P2Y1 inhibitors and in
P2Y1 knockout mice. Importantly, P2Y1 knockout and inhibition of P2Y1 by pharmacological inhibitors
reduced diarrhea, indicating that P2Y1 is responsible for the global effects of rotavirus infection.
Conclusions: These findings suggest that the signaling molecule ADP and its receptor P2Y1 may be a new
target to treat and lessen rotavirus-induced diarrhea.
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Clinical-Translational Science
Risk and predictors of late lower cranial neuropathy in long-term oropharyngeal cancer survivors
Puja Aggarwal1,5, Ryan P. Goepfert1, Adam S. Garden2, Naveen Garg3, Jhankruti S. Zaveri1, Xianglin L.
Du5, Michael Swartz5, Stephen Y. Lai1, C. David Fuller2, Renata Ferrarotto4, Linda B. Piller5, Katherine A.
Hutcheson1,2
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Background: Lower cranial neuropathy (LCNP) is a rare, but permanent, late effect of radiotherapy (RT)
and other cancer therapies. LCNP is associated with excess cancer-related symptoms, worse swallowingrelated quality of life (QoL) and long-term feeding tube dependence, aspiration pneumonia, and
tracheostomy. Previous studies examining LCNP have been case reports or small cohorts of predominantly
nasopharyngeal cancer (NPC) survivors. Few studies have investigated risk and predictors of late LCNP
among oropharyngeal cancer (OPC) survivors. The overall objective of this paper is to quantify the
cumulative incidence of late LCNP and identify clinical predictors of late LCNP among long-term OPC
survivors.
Methods: Disease-free, adult oropharyngeal squamous cell carcinoma (OPSCC) survivors who completed
curative treatment between January 2000 and December 2013 and consented to participation in research
were included in the study. Exclusion criteria: baseline LCNP, recurrent head and neck cancer, treatment at
other institutions, deceased status, secondary primary malignancy (SPM)/persistent/recurrent malignancy of
the head and neck < 3 months after treatment. This study included 2021 of 3627 OPSCC survivors with
median survival of 6.8 years (range: 0.3-18.4; IQR: 4.3-10.2). Late LCNP events were defined by
neuropathy of the glossopharyngeal (IX), vagus (X), and/or hypoglossal (XII) nerves ≥ 3 months after
cancer therapy. Cumulative incidence of LCNP was estimated using the Kaplan Meier method with
adjustment for competing risks using time to event as the underlying metric. Log-rank test was used to
assess differences between groups by LCNP status, and multivariable Cox proportional hazard models were
fit.
Results: Eighty-eight OPC survivors(4.4%) were diagnosed with late LCNP with median time to LCNP
onset after treatment of 5.4 years (range: 0.3-14.1; IQR: 1.6-8.5). Cumulative incidence of LCNP among all
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OPC survivors was 0.02 (95% CI: 0.02-0.03), 0.06 (95% CI: 0.05-0.08), and 0.10 (95%CI: 0.07-0.13) at 5
years, 10 years, and 15 years of follow-up, respectively. Multivariable Cox regression identified T4 stage vs
T1 stage (HR: 3.82; 95%CI: 1.85-7.86, p<0.001) and accelerated RT fractionation vs standard RT
fractionation (HR2.15, 95%CI 1.34-3.45, p=0.002) as independently associated with late LCNP status,
adjusting for age, subsite, T-stage, smoking, and therapeutic modality.
Conclusions: While rare in the population overall, risk of late LCNP progressed over time to 10%
cumulative risk over survivors’ lifetimes. Our prediction model identified OPC survivors who had T4
tumors and those who received accelerated fractionation RT as having a higher risk of late LCNP. Further
efforts are necessary to investigate the risk of and predictors for this disabling late effect of cancer treatment
experienced by growing numbers of relatively young OPC survivors who are expected to survive decades
after treatment.
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Enhancing adoptive T cell therapy by depleting endogenous TGF-β1 in human CD8+ T cells
Yongming Xue1, Farah Hasan1,2, So Hyun Park3, Ke Pan1, Gang Bao3, Cassian Yee1,2,4
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Background: Adoptive cell therapy (ACT)—whereby tumor-reactive T lymphocytes are isolated from
peripheral blood or tumor tissue and/or genetically engineered, expanded in vitro, and infused into
patients—can induce clinical responses in patients with leukemia, lymphoma, metastatic melanoma, and
other malignancies. However, a means to generate superior T cells with enhanced anti-tumor efficacy
remains highly desirable. Because of the suppressive role of TGF-β1 on the effector functions of CD8+ T
cells, T cells have been engineered to express the dominant negative form of TGF-β receptor (TGFBRIIDNR) or to knock out TGF-β receptor in order to block the reception of extrinsic TGF-β1 and maintain the
T cells’ antitumor function in a hostile microenvironment. However, CD8+ T cells require the TGF-β1 signal
to develop into resident memory T cells (TRM), which is potentially crucial to the long-term antitumor effect
of ACT. Therefore, these current strategies abrogate CD8+ T cells’ ability to form TRM.
Methods: In order to overcome this disadvantage, we developed a novel approach to enhance the effector
function of CD8+ T cells without abrogating formation of TRM by CRISPR/Cas9-mediated knockout of
endogenous TGF-β1-encoding gene TGFB1 in CD8+ T cells.
Results: A gRNA specifically targeting the 5’ of TGFB1 CDS efficiently diminished the levels of both
membrane-bound and soluble forms of TGF-β1. Compared with non-target (NT) gRNA control cells,
TGFB1-depleted CD8+ T cells induced significantly greater production of cytokines such as IFN-γ, TNF-α
and granzyme B after α-CD3/α-CD28 bead stimulation. Importantly, TGFB1 knockout in CD8+ T cells did
not dramatically affect the capability to form TRM in response to exogenous TGF-β1 and hypoxia. In the
TCR-T cells engineered to express gp100-specific, HLA-A*0201-restricted TCR, we found that TGFB1depleted TCR-T cells showed dramatically enhanced cytolytic activity and significantly greater IFN-γ,
TNF-α and granzyme B when co-cultured with gp100+ tumor cell line Mel526, compared with NT control
TCR-T cells. Interestingly, even in the presence of high-dose exogenous TGF-β1, TGFB1-depleted TCR-T
cells maintained greater efficiency than NT control in killing Mel526 target cells.
Conclusions: Our findings support the application of endogenous TGFB1 knockout to in vitro generation of
human antigen-specific CD8+ T cells with enhanced effector properties for adoptive T cell therapy.
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Physician perspectives on non-alcoholic fatty liver disease
Natalia I. Heredia1, Jessica Hwang2, Larking Strong1, Maya Balakrishnan3, Lorna H. McNeill1
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Background: Non-alcoholic fatty liver disease (NAFLD) is now the leading cause of liver disease in the
U.S. Without intervention, some NAFLD patients may progress to more severe forms of the disease,
including liver cancer. Primary care physicians (PCPs) are often the first point of contact, and may be the
only available resource, for many patients with NAFLD. Early studies suggest inadequate knowledge
among PCPs about diagnostic and management approaches for NAFLD. The purpose of this qualitative
study was to understand PCP knowledge and practices about NAFLD diagnosis and management.
Methods: We conducted in-depth interviews with PCPs in the greater Houston area. PCPs completed
written informed consent and a brief demographics form prior to the interview. Interviews were 30 to 45
minutes in length; they were recorded and later transcribed. Interview questions covered knowledge of
NAFLD progression, varying incidence by racial/ethnic status, current clinical practice for diagnosing and
managing NAFLD, and perceptions of the burden of NAFLD on patients, among other topics. We used
NVivo to analyze the transcripts.
Results: PCPs (n=14) practiced internal or family medicine, with a wide range of experience (1.5 to 30
years). We found variations in NAFLD diagnosis and management across practices and by insurance status.
The typical diagnosis process involved assessment of liver enzymes, either as part of annual routine blood
panels or workup for other conditions, and, if liver enzymes were elevated, proceeding to liver imaging. For
patients with abnormal liver imaging, if they had insurance or were within a safety net health system, PCPs
usually referred them to hepatologists/gastroenterologists. For uninsured patients outside the safety net with
persistently elevated liver enzymes, PCPs sometimes proceeded with lifestyle modification
recommendations, given concerns about ability to access imaging services or see a specialist. There was
wide variation in the role PCPs play in the management of NAFLD. Some physicians used motivational
interviewing and helped patients set dietary and physical activity goals, while others simply gave verbal
recommendations and/or referred patients to a dietician. Several PCPs expressed frustration with the lack of
guidance for screening and management of NAFLD.
Conclusions: The process of diagnosing and managing NAFLD appears to vary widely and may be
influenced by a patient’s insurance status and clinic-specific practices. Given the growing burden of
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NAFLD on the U.S. medical system, efforts are needed understand the knowledge and clinical practice
patterns of PCPs to support them in their frontline role.
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Individual differences associated with lung cancer screening uptake
Kristin G. Maki1, Kiaping Liao1, Lisa M. Lowenstein1, Maria A. Lopez-Olivo1, Robert J. Volk1
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Background: Lung cancer is a leading cause of cancer-related death in the United States among males and
females. Specifically, less than 1 in 5 (18.6%) individuals with lung cancer will survive 5 years past
diagnosis. Lung cancer screening (LCS) with low-dose computed tomography (LDCT) has been shown to
reduce lung cancer deaths. This study examines individual factors associated with obtaining LCS among
individuals enrolled in a study on the effects of a patient decision aid about LCS.
Methods: This is a secondary analysis of a randomized clinical trial conducted with 13 state tobacco
quitlines’ clients. Participants who met age and smoking history eligibility for LCS were enrolled (March
2015 to September 2016) and followed up for 6 months (until May 2017). Only participants (n = 204)
randomized to the patient decision aid condition were included in the present study. The outcome is
dichotomized to reflect obtaining LCS by the 6-month follow-up (1 = obtained screening). Key independent
variables include participants’ perceived importance of early detection; concern about radiation exposure,
false alarms, and overdiagnosis; and anticipated regret. Demographics, practical barriers, and knowledge
about lung cancer screening were included as control variables. The data were analyzed using logistic
regression in SPSS (version 24).
Results: Participants who knew how to find a screening program were 1.59 times (95% CI: 1.37, 17.50)
more likely to be screened than those who were unclear about where to go for screening. Similarly,
participants who knew if their insurance covered LCS were 1.55 times (95% CI: 2,14, 10.47) more likely to
be screened than those who did not know. Participants who were very concerned (rated as 9-10) and
concerned (rated as 5-8) about overdiagnosis were respectively 1.85 (95% CI: 0.04, 0.61) and 1.88 (95% CI:
0.04, 0.53) times less likely to have been screened than those with lower ratings of concern about
overdiagnosis. In contrast, participants who expressed a high level of anticipated regret (rated 10) were 1.70
times (95% CI: 1.71, 17.37) more likely to be screened than those who reported lower levels of anticipated
regret about not being screened and later being diagnosed with lung cancer.
Conclusions: The study’s findings suggest that anticipated regret about not obtaining screening and later
being diagnosed with lung cancer is associated with LCS behavior. Conversely, concern about
overdiagnosis, and practical barriers, may be associated with not obtaining LCS. Future research will benefit
from further examining psycho-social values in this context.
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Developing the mesenchymal tissue landscape as a scRNA-seq based metric of liposarcoma
differentiation
Danh D. Truong1, Allen Tannenbaum2, Bridgette L. King1, Salah-Eddine Lamhamedi-Cherradi1, Neeta
Somaiah1, Barry W. Feig3, Joseph Ludwig1
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Background: Liposarcoma (LS) is a common soft tissue sarcoma originating from white adipose tissue.
Multiple LS subtypes exist, but the two most common include well-differentiated LS (WDLS), which is
morphologically similar to normal fat, and dedifferentiated liposarcoma (DDLS), an aggressive variant that
can appear de novo or evolve through dedifferentiation of WDLS later in a patient’s disease course. While
current treatment strategies using cytotoxic chemotherapy have a modest therapeutic effect, an untested
approach would aim to directly intervene in the molecular pathways that promote LS dedifferentiation or
relieve the blockade that prevents the orderly differentiation of DDLS. To measure whether candidate
therapies modulate differentiation, we need a quantitative metric of cell differentiation that presently does
not exist. Herein, we describe a novel scRNA-seq–based mesenchymal tissue landscape (MTL) of cell
differentiation, akin to Waddington’s landscape, which will be used to decipher the regulatory networks that
distinguish between DDLS and WDLS.
Methods: We performed scRNA-seq and scATAC-seq at frequent time points as mesenchymal stem cells
(MSCs) were driven toward an adipogenic or osteogenic cell fate ex vivo by culturing upon hydrogels of
varying stiffness, a property known to regulate MSC lineage commitment. Next, single-cell transcriptomic
data were analyzed in the context of a signaling network entropy measure to create the MTL that allows one
to quantify and visualize the differentiation states of individual tumor specimens. We hypothesized that: 1)
DDLS should cluster closely to early adipocyte differentiation on the MTL, and 2) comparing DDLS and
WDLS transcriptome to the gene networks regulated during adipogenesis will identify dysregulated gene
networks responsible for differentiation arrest.
Results: As a precursor to the study of LS or other sarcomas, we validated gene signatures of MSCs,
adipocytes, and osteoblasts. Next, we identified gene expression programs that are temporally regulated
during MSC differentiation. We quantified differentiation by signaling entropy and showed that MSCs had
higher differentiation potential than adipocytes and osteoblasts. ScATAC-seq revealed enriched motifs as
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potential regulators of adipogenesis and osteogenesis. Having created an MTL enabling our team to quantify
differentiation with precision, we are currently sequencing human DDLS and WDLS specimens to identify
the dysregulated gene networks and proteins responsible for differentiation blockade.
Conclusions: Understanding the molecular mechanisms that underpin LS plasticity and differentiation may
provide a roadmap to develop new biologically targeted therapies able to regulate cell fate. The MTL may
also offer new insights for osteosarcoma and rhabdomyosarcoma, pediatric sarcomas that exhibit
dysregulated differentiation.
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MMP-7 increases migration by decreasing E-cadherin and F-actin localization at cell-cell contacts in
prostate cancer micro-tumors formed by perlecan/HSPG2
Lissette A. Cruz1, Tristen V. Tellman1, Brian J. Grindel1, 2, Daniel D. Carson2, Mary C. Farach-Carson1,2
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Background: Polarized epithelium is maintained by cell-cell interactions via cadherins and cell adhesion
molecules (CAMs). Interactions are stabilized further by cell-matrix interactions on the basement
membrane, where perlecan/HSPG2 is a major component that controls signaling in resting tissues with
unperturbed matrices. Proteolytic cleavage of perlecan increases cell-matrix interactions and dysregulates
cell signaling, permitting migration. Previous studies showed that perlecan domain IV-3 (DmIV-3) drives
cell cohesion and, when digested with matrix metalloproteinase-7 (MMP-7), drives cell dyscohesion. In
vivo, prostate cancer (PCa) patients with bone metastases have circulating DmIV fragments, with negative
correlation between MMP-7 staining and loss of perlecan in tissue samples. MMP-7 can cleave cadherins
and other CAMs disrupting cell-cell adhesions. Also, DmIV-3 fragments generated by MMP-7 cleavage
may further induce cell dyscohesion by disrupting interactions between CAMs and/or cadherins.
Methods: To evaluate the impact of MMP-7 and DmIV-3 fragments on cell migration or cluster
dyscohesion, uniformly sized PCa cell clusters were pre-formed using a microwell system, enabling control
of cluster size and cell number. Pre-formed cell clusters were transferred to DmIV-3–coated wells for 16-24
hours. Clusters then were treated with MMP-7 alone or MMP-7 plus DmIV-3 fragments during live cell
imaging. Immunofluorescent staining and Imaris analysis of fixed cell clusters at different stages of
cohesion and dyscohesion was performed to determine cytoskeletal architecture. The alignment of Ecadherin and F-actin served as a quantitative measure of cohesion.
Results: PCa cell clusters maintained strong cell-cell contacts with intact DmIV-3. In contrast, pre-formed
PCa cell clusters cultured in the presence of DmIV-3 cleaved by MMP-7 showed dyscohesion and increased
cell migration initiated at the cluster edges where migratory velocity was highest. Pre-formed PCa cell
clusters treated with MMP-7 had increased F-actin reorganization during various stages of PCa cell cluster
dyscohesion. E-cadherin and F-actin co-alignment at cell-cell contacts was reduced in PCa cell clusters
treated with MMP-7 and DmIV-3 fragments, particularly at the edges where cell-cell adhesion was lowest
and cell-matrix interactions were highest.
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Conclusion: Following patterns of dyscohesion of pre-formed PCa microtumors provides a good model to
study dynamic changes in protein components involved in cell-cell interactions and quantitate cell migration
patterns as they can occur in metastasis and circulating tumor cell formation. Actin reorganization promotes
a migratory cell phenotype in PCa cell clusters treated with MMP-7 and DmIV-3 fragments. Future studies
aim to identify DmIV3 fragment(s) positively associated with tumor dyscohesion that may play key roles in
secondary metastasis formation.
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Agranular mice expose the mechanistic link between small cerebellar size and neurodevelopmental
disorders in preterm infants
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Background: Abnormal cerebellar development instigates motor diseases and neurodevelopmental
disorders including ataxia, dystonia, tremor, and autism. These conditions are highly prevalent in premature
infants and in newborns with cerebellar hemorrhage, who ultimately attain a smaller cerebellar size
compared to children born full-term. The small cerebellar size in surviving preterm infants is likely due to
halted granule cell neurogenesis that typically occurs in the third trimester in human and first two postnatal
weeks in mice. However, it remains elusive how abnormal granule cell neurogenesis effects cerebellar
guided behaviors. Here, we test the hypothesis that granule cell neurogenesis is essential for the structural
and functional development of Purkinje cells, which are the primary recipients of granule cell synapses and
function as the main computational unit in the cerebellar cortex.
Methods: We used regional genetic manipulations and in vivo electrophysiology to test whether granule
cells help establish the firing properties of Purkinje cells during postnatal mouse development. We
generated mice that lack granule cell neurogenesis and tracked the structural and functional consequences
on Purkinje cells. We also investigated how lack of granule cell neurogenesis effects cerebellum-guided
motor performance and social behaviors in neonatal pups.
Results: We revealed that without granule cell neurogenesis, Purkinje cells failed to acquire their typical
adult connectivity and morphology. In agreement with these anatomical abnormalities, we showed that
Purkinje cell firing patterns in 2-week-old agranular pups was different from aged-matched control
littermates and instead resembled firing patterns found in 1-week-old control pups. Thus, Purkinje cells need
granule cells for their structural and functional maturation. In addition to abnormal Purkinje cell
development, agranular pups had abnormal righting reflexes, dystonic postures, tremor, and diminished
vocalization when separated from their mothers, a measure for social behavior in neonatal mice.
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Conclusions: These data argue that granule cell neurogenesis sets the maturation time window for Purkinje
cell function and refines cerebellar-dependent behaviors. Our findings show that abnormal granule cell
neurogenesis leads to immature Purkinje cell function and explain how small cerebellums lead to behavioral
deficits in surviving preterm infants.
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PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and
facilitates tumor necrosis
Junwei Hou, Weiya Xia, Chiung-Wen Chang, Yun You, Jung-Mao Hsu, Yun Wu, Mien-Chie Hung
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center,
Houston, TX.
Background: Cleavage of gasdermin D (GSDMD) by caspase-1, -4, -5, or -11 defines the canonical
pyroptosis pathway. Among all six human gasdermins, five are associated with important biological
functions; gasdermin C (GSDMC) is the only one whose biological function has not yet been identified.
Nuclear localization of PD-L1 (nPD-L1) has been reported, but its function and translocation mechanism
are unclear. In solid tumors, tumor-associated macrophages, which secrete TNFα, tend to accumulate within
necrotic foci. TNFα has long been known to induce tumor necrosis, but the molecular mechanism by which
it does so has been poorly understood.
Methods: We used cellular fraction and Duolink assay to determine nPD-L1 expression level under
hypoxia. We then established 4T1 and MDA-MB-231 stable cells with enforced expression of PD-L1-WT
(wild-type PD-L1), PD-L1-NLS (nuclear localization signal-mutated PD-L1), and PD-L1-NES (nuclear
export signal-mutated PD-L1). We treated these cells with TNFα plus CHX under hypoxia to determine cell
death patterns and used RT-PCR and immunoblotting to detect the expression of gasdermins. A panel of
caspases was used to screen for the one that cleaves GSDMC. GSDMC and caspase-8 were depleted to
confirm their involvement in the nPD-L1-mediated pyroptosis pathway. Bioinformatic and mutation
analysis was used to determine the cleavage site of GSDMC, followed by functional assay to test the
biological function of the N-terminal domain of GSDMC. Biological function of nPD-L1-mediated
pyroptosis pathway was investigated in vivo using the stable cells above and further confirmed by clinical
data.
Results: Here, we showed that PD-L1 switched TNFα-induced apoptosis to pyroptosis in cancer cells,
resulting in tumor necrosis. Under hypoxia, p-Stat3 physically interacted with PD-L1 and facilitated its
nuclear translocation, enhancing GSDMC gene transcription. GSDMC was specifically cleaved by caspase8 with TNFα treatment, generating a GSDMC N-terminal domain that formed pores on the cell membrane
and induced pyroptosis. We also found that nuclear PD-L1, caspase-8, and GSDMC are required for
macrophage-derived TNFα-induced tumor necrosis in vivo. nPD-L1-mediated tumor necrosis shortened
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mouse survival, which was worsened in an immune-dependent manner. Moreover, high expression of
GSDMC correlated with poor survival.
Conclusions: Hypoxia induces nPD-L1 translocation through p-Stat3. PD-L1 harbors transcriptional
activity to activate GSDMC expression. Cancer cell pyroptosis via hypoxia/nPD-L1/GSDMC axis causes
tumor necrosis. nPD-L1-driven tumor necrosis correlates with poor survival in mice and patients, which is
worsened in an immune-dependent manner. The pyroptosis pathway in cancer cells is non-canonical and
differs from that in macrophages.
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Dinutuximab inhibits triple-negative breast tumor growth by targeting GD2+ breast cancer stem-like
cells
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Background: Breast cancer stem-like cells (BCSCs) are reported to be a major contributing factor for
metastatic spread of the disease and chemotherapy resistance in triple-negative breast cancer (TNBC).
Currently, no available therapeutic tools target BCSCs. We previously reported that the ganglioside GD2 is
highly expressed on BCSCs and that inhibition of its expression hampers TNBC growth in xenograft
models. Therefore, we hypothesized that the anti-GD2 monoclonal antibody dinutuximab (chimeric 14.18)
targets GD2+ BCSCs and inhibits TNBC growth.
Methods: Dinutuximab is FDA approved for the treatment of GD2+ tumors in neuroblastoma. We evaluated
the effects of dinutuximab on TNBC cell adhesion, migration, and mammosphere formation. We also
investigated the effects of dinutuximab on cell signaling. Finally, we performed in vivo studies using TNBC
xenograft and patient-derived xenograft (PDX) models to demonstrate the efficacy of dinutuximab in
inhibiting tumor growth.
Results: In the present study, we assessed the baseline GD2 expression in more than 25 breast cancer cell
lines, including TNBC and estrogen receptor (ER)+, progesterone receptor (PR)+, and Her2+ cell lines as
well as TNBC PDX-derived cells and observed a higher median (± standard deviation) percentage of GD2+
cells in TNBC cell lines (6.2 ± 0.7) compared to ER+PR+ and Her2+ cell lines (2.1 ± 0.2). Furthermore,
compared with rituximab (as negative control), treatment with dinutuximab significantly decreased adhesion
and formation of mammospheres by TNBC cells (MDA-MB-231 and SUM159) as well as the cells’ ability
to migrate toward a serum-rich medium. Interestingly, treatment of TNBC cells with dinutuximab
significantly decreased phosphorylation of mTOR, ERK, and 4E-BP1, indicating that dinutuximab inhibits
the mTOR pathway by targeting GD2 in TNBC cells. In addition, treatment with the combination of
dinutuximab and NK cells substantially decreased the number of GD2-expressing cells and induced
apoptosis in TNBC cells. Moreover, treatment with dinutuximab dramatically reduced tumor growth in an
MDA-MB-231 xenograft model using nude mice (15 fold, p<0.0001). Finally, the combination of
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dinutuximab and activated human NK cells synergistically reduced TNBC PDX tumor volumes in an NSG
mouse model and increased survival (p<0.0001).
Conclusion: We demonstrated that GD2 expression is upregulated in TNBC and that targeting GD2 with
the anti-GD2 antibody dinutuximab inhibits BCSC function. The combination of dinutuximab and NK cells
induces apoptosis in GD2+ TNBC cells through ADCC. The data from TNBC xenograft and PDX models
provide proof of concept for the criticality of GD2 positivity in BCSCs and establish dinutuximab as a
potentially efficacious therapeutic approach for TNBC.
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Sensitivity enhancement of an experimental benchtop X-ray fluorescence imaging system through the
firmware upgrade on a commercial single crystal cadmium telluride detector system
Hem Moktan, Sandun Jayarathna, and Sang Hyun Cho
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Purpose: To investigate the sensitivity enhancement of an experimental benchtop X-ray fluorescence (XRF)
imaging/XRF computed tomography (XFCT) system by implementing the latest firmware on a commercial
single crystal cadmium telluride (CdTe) detector system.
Method: A commercial single crystal CdTe detector system with the latest firmware was characterized to
operate at a higher bias voltage of 700 V and fast (3.2 µs) peaking time. Using this detector system as well
as the existing/old detector system in benchtop XRF/XFCT imaging settings, the Compton/XRF spectra
from small (8 mm in diameter) gold nanoparticle (GNP)-containing phantoms were acquired. During these
measurements, the GNP-containing phantoms were irradiated with a polychromatic X-ray source operated
at 125 kVp/24 mA and filtered with 1.8 mm tin. Single-hole detector collimators with two different aperture
sizes (2 and 3 mm) were used. Gold K-shell XRF signals were extracted from the acquired spectra and used
to determine the calibration curve for each experimental condition.
Results: The detector system with the latest firmware produced relatively low dead time under high X-ray
flux, suggesting its improved photon counting efficiency. Additionally, this detector system was stable and
performed well with a spectral resolution of ~0.7 keV FWHM at 69 keV photon energy. With the identical
(2-mm aperture) detector collimator and scan time of 10 s, this detector system scored nearly 50% more
gold XRF signals than the existing detector system at all GNP concentrations tested. This resulted in the
sensitivity enhancement of the XRF/XFCT imaging system, giving rise to the GNP detection limit of 0.02
wt. %, which was better than that achievable with the existing detector system (0.03 wt. %). When
combined with the detector collimator with a larger (3-mm) aperture, the detector system with the latest
firmware produced drastically more gold XRF signal at a given GNP concentration (e.g., 9 times more for 1
wt. % GNP solution and scan time of 10 s), leading to further reduction in the GNP detection limit (i.e., 0.01
wt. %).
Conclusion: Significant performance enhancement of an experimental benchtop XRF/XFCT imaging
system, in terms of the system sensitivity, was achieved by implementing the latest firmware on a
commercial single crystal CdTe detector.
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Proper platelet generation requires a functional PTIP-MLL3/4 axis-mediated epigenetic modification
during megakaryocytic differentiation
Woori Bae, Prosun Das, Hieu T Van, Margarida A Santos
Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer
Center, Houston, TX.
Background: Platelets mediate hemostasis and thrombosis, and various factors promote platelet activation
in response to immune signals. Although major signaling pathways and transcription factors have been
shown to play crucial roles in platelet biogenesis (thrombopoiesis), the epigenetic regulation of this process
and the key epigenetic regulators involved are not as well known. The ubiquitously expressed PAX
transactivation domain-interacting protein-1 (PTIP), also known as MLL3/4 complex adaptor protein, is
essential for gene regulation and cellular differentiation. However, a role for PTIP in thrombopoiesis has not
been previously identified.
Methods: Here we will perform functional and mechanistic assays on Ptipf/f Pf4-cre, Mll3f/f Mll4f/f Pf4cre,
Mll3f/f Pf4cre, and Mll4f/f Pf4cre mice to define the overlapping roles of PTIP, MLL3, and MLL4 in
platelet generation. These include flow cytometry analysis to characterize different megakaryocyte (MK)
populations, electron and fluorescence microscopy to assess MK maturation and proplatelet
formation/platelet release, platelet depletion and lifespan assays, and in vitro fetal liver (FL)-derived MK
cultures. We will validate overexpresses/downregulated genes by modulating their expression in FL-derived
MK cultures using CRISPR-Cas9–mediated depletion and lentivirus-mediated overexpression. To define the
direct targets of PTIP and MLL3/4 in thrombopoiesis, we will perform RNA sequencing and chromatin
immunoprecipitation sequencing (ChIP-seq) with our validated PTIP antibody in wild-type and PTIPdeficient cultured FL-derived MKs to identify PTIP-direct targets.
Results: We found that PTIP deletion led to dramatically reduced blood platelet counts and slightly
increased mean platelet volume. MLL4 deletion also affected platelet counts, although the effect was not as
strong as that of PTIP deletion. The number of MKs was significantly increased in PTIP-deficient mice.
Nonfunctional platelets were constantly cleared from the circulation in the spleen and liver, and PTIPdeficient platelets were rapidly removed. Interestingly, PTIP recruited methyltransferases to chromatin to
enable the transcription of target genes.
Conclusions: Taken together, our data identify PTIP as a chromatin regulator of thrombopoiesis that is
required for directly modulating thrombopoiesis-specific gene expression together with MLL3/4.
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Metabolic stress induces glutamine-dependent GD2+ breast cancer stem cell-like phenotype
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Background: Nutrient deprivation is one of the hallmark conditions of the tumor microenvironment. The
rapid growth of the tumor leads to the development of a hypoxic and nutrient-deprived microenvironment
within the core of the tumor mass due to an insufficient blood supply. Here we hypothesized that nutrient
deprivation-induced metabolic stress results in a breast cancer stem cell-like (BCSC) phenotype in triple
negative breast cancer (TNBC) cells.
Methods: TNBC cell lines SUM159 and MDA-MB-231 were cultured under serum- or glucose-deprived
conditions for 3-5 days. Expression of a BCSC marker, ganglioside GD2, was measured by flow cytometry.
Mass spectrometry analysis was used to study the metabolic pathways in GD2+ cells, followed by carbon
and nitrogen tracing experiments with labelled glutamine. Glutathione levels and reactive oxygen species
(ROS) in TNBC cells were measured by flow cytometry.
Results: Compared to serum-rich conditions, we found that serum-deprived conditions result in significant
upregulation of GD2+ cells: from 9%±2% to 26%±5% in MDA-MB-231 and 7%±2% to 29%±5% in
SUM159 cells. Interestingly, this effect was compensated when the cells were supplemented with serumrich medium. In addition, a positive correlation was observed between GD2+ cell number and tumor volume
in vivo, suggesting that metabolic stress in the growing tumors results in a GD2+ phenotype in TNBC cells.
Next, TNBC cells cultured under glucose deprivation or in the presence of glycolysis inhibitor 2-deoxy
glucose (2DG) showed a 2-fold increase in GD2+ cells compared to cells cultured with glucose (6 g/L) or
without 2DG, suggesting that glucose deprivation enhances GD2 expression. Global metabolomic profiling
by mass spectrometry followed by ingenuity pathway analysis identified signatures such as glutathionemediated detoxification and glutathione biosynthesis to be more highly upregulated in GD2+ compared to
GD2- cells. Furthermore, we found that glutamine, a key component of glutathione biosynthesis,
upregulated the percentage of GD2+ cells. Moreover, carbon and nitrogen tracing using 13C- and 15Nlabeled glutamine by mass spectrometry showed its direct contribution to GD2 biosynthesis. Treatment with
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a glutamine transporter inhibitor, V9302, reduced GD2+ cell number by 70%-80% in a dose-dependent
manner. V9302 also inhibited soft-agar colony and mammosphere formation in TNBC cell lines. In
addition, V9302 reduced cellular glutathione and increased cellular ROS levels.
Conclusion: Metabolic stress results in a GD2+ BCSC phenotype in TNBC cells. Inhibition of glutamine
uptake using V9302 negatively regulates the GD2+ BCSC phenotype and alters redox homeostasis in
BCSCs. Targeting glutamine transporter could complement conventional chemotherapy by targeting BCSCs
in TNBC.
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Differential expression of transcription factors highlights therapeutic vulnerabilities of four SCLC
subtypes
Elizabeth M. Park1, Carl M Gay, C Allison Stewart, Lixia Diao2, Qi Wang2, Robert J Cardnell1, Jing Wang2,
John V Heymach1, Lauren Averett Byers1
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Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy that
accounts for 15% of lung cancer diagnoses. The severity of this disease is exacerbated by the fact that there
are few therapeutic options, which mostly offer limited clinical benefit, culminating in a 5-year survival rate
of <7% across all stages of disease. SCLC therefore has an urgent, unmet need for both mechanistic
understanding of disease progression and the development of novel, targeted therapeutics with high
efficacy.
Methods: To identify transcriptional subtypes, we used non-negative matrix factorization of gene
expression data from 81 SCLC tumors and identified four subtypes largely based on differential expression
of the transcription factors ASCL1, NEUROD1, and POU2F3. We hypothesized that these subtypes may
underlie unique therapeutic vulnerabilities. We compared sensitivity of each of these four subtypes to over
500 anticancer therapies. We also examined differential expression of genes that encode surface-expressed
proteins that may be targetable by reagents such as therapeutic antibodies or antibody-drug conjugates
(ADCs).
Results: We showed that certain subtypes of SCLC had higher sensitivity to targeted inhibitors than others.
For example, SCLC-P showed the most sensitivity to standard of care cisplatin and PARP inhibitors, while
SCLC-N had the highest sensitivity to AURK inhibitors. Additionally, we identified a total of 60 candidate
genes that encode surface proteins that are differentially expressed across the four subtypes of SCLC.
Within these 60 candidates, we have identified a few, such as CEACAM5 and SSTR2, for which there exist
clinically available, targeted ADCs.
Conclusions: The underlying biology defining our four identified subtypes of SCLC can explain certain
vulnerabilities to clinically available treatments such as PARP or AURK inhibitors or cisplatin. It also has
revealed a striking number of targetable, differentially expressed surface proteins, some of which already
have clinically available reagents that could be repurposed for treatment of SCLC on a subtype-specific
basis.
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ERK acts as a timer to regulate meiotic progression and oocyte number
Debabrata Das, Shin-Yu Chen, Swathi Arur
Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston TX.
Background: Meiosis-I is essential for genetic diversity and reduction of genomic copy number in all
sexually reproducing organisms. This evolutionarily conserved process is governed by a series of highly
timed events of chromosome behaviors. An error in any step results in organismal sterility or failures in
embryonic development. However, the nature of the timer in space that interprets, coordinates, and monitors
the chromosome behavior during meiosis-I remains unknown.
Results: To address this question we used C. elegans oogenic germline, in which stages of meiosis-I are
spatiotemporally coordinated. We observed that precocious spatial ERK activation in RAS gain of function
(gf) mutants triggered completion of pachytene spatially early and entry into premature gametogenesis and
oocyte formation. This led to the formation of multiple small oocytes that displayed high level of sterility
and embryonic lethality. Conversely, absence of active ERK in ERK loss of function (lf) mutant delayed
meiotic progression, and germ cells halted at pachytene stage for a prolonged period, resulting in loss of
oocyte number as well as sterility and embryonic lethality. Since maintenance of synaptonemal complex
(SC) between homologous chromosomes and crossover formation takes place in pachytene-stage germ cells,
we hypothesized that the RAS/ERK pathway regulates either or both of these processes. Depletion of him-3,
an axial element protein of SC, but not spo-11, a DNA double strand break protein, by RNA interference
rescued the multiple oocyte phenotype in RAS(gf) mutants, suggesting that ERK signaling may regulate
meiosis progression through SC functioning. In vitro ERK2 kinase assays on all of the seven purified
recombinant SC proteins identified that ERK directly phosphorylated HTP-1 at Serine 325. Consistent with
this, phosphorylated HTP-1 accumulated in a manner overlapping with ERK activation, as assayed with
phospho-specific HTP-1(S325) antibody. Lack of HTP-1 phosphorylation (in CRISPR/Cas9-mediated
genetically modified phospho-null allele, HTP-1[S325A]) led to asynapsis and persistence of meiotic double
strand breaks, causing delayed meiotic progression. Moreover, HTP-1(S325A) rescued the multiple oocyte
phenotype in RAS(gf), while phospho-mimetic HTP-1(S325E) rescued the loss of oocyte number in ERK(lf)
mutants.
Conclusions: Taken together, we identified that spatial activation of ERK in the pachytene region acts as a
timer of meiosis-I, which coordinates SC maintenance through HTP-1(S325) phosphorylation with the rate
of meiotic progression. This work shows a previously unknown link between chromosomal behavior and
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oocyte number. Given the conservation of female meiosis-I across species, we speculate that a similar
signaling-based mechanism may be operative in mammals to regulate oocyte number.
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Dual MEK and AXL inhibition targets tumor cell heterogeneity in NSCLC to prevent resistant
outgrowth mediated by EMT
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Background: The epithelial-to-mesenchymal transition (EMT) is a dynamic epigenetic reprogramming
event that occurs in a subset of tumor cells and is an initiating step to cancer invasion and distant metastasis.
The process is reversible and gives a plasticity to cancer cells to survive under variable conditions, with the
acquisition of cancer stem cell-like characteristics and features such as drug resistance. Therefore,
understanding survival dependencies of cells along the phenotypic spectrum of EMT will provide better
strategies to target the spatial and temporal heterogeneity of tumors and prevent their ability to bypass single
inhibitor treatment strategies.
Methods: To address this, we integrated the data from a selective drug screen in epithelial and
mesenchymal Kras/p53 (KP) mutant lung tumor cells with separate datasets including reverse phase protein
array and an in vivo shRNA dropout screen to reveal specific epithelial and mesenchymal survival
dependencies. Because EMT is a dynamic process, we also incorporated a dual fluorescence EMT sensor
system (the Z-cad sensor) into our murine KP lung cancer models to observe real-time changes in the
epigenetic state of tumor cells when treated with drugs identified from the screens. Treatment efficacy was
investigated in 2D, 3D and in vivo model systems.
Results: The orthogonal approaches combining 3 individual datasets on epithelial and mesenchymal
NSCLC tumor cells identified AXL and PARP as potential mesenchymal cell survival dependencies and
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MEK and AKT as epithelial dependencies. Further investigation revealed that MEK and AXL inhibitors
worked synergistically in decreasing the viability of murine NSCLC cells, likely by differential targeting of
EMT subpopulations and prevention of EMT-mediated drug resistance. Similarly, co-targeting MEK and
AXL in vivo revealed that the combination treatment was more efficacious than either single agent at
controlling the tumor growth and metastasis of a highly metastatic murine NSCLC cell line.
Conclusions: Together, our data provide a rational drug combination that co-targets the MEK and AXL
signaling pathways in NSCLC tumors. This combination works synergistically to selectively target cells in
an epithelial or mesenchymal phenotypic state, leading to significant repression of tumor growth and
prevention of resistant outgrowth by targeting EMT-related tumor heterogeneity.
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Developing oxidative stress-resistant CAR-T for solid tumors
Allison J Nipper1, Emilie AK Warren1, Caroline E Porter2,3, Tim Sauer3, Mariana Villanueva1, Hugo
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Background: High levels of oxidative stress in the solid tumor microenvironment inflict cellular damage
and alter functionality of tumor-infiltrating lymphocytes. The hostile environment of solid tumors therefore
poses a challenge to immunotherapy, which moderates the action of immune cells to combat tumor growth.
As a result, T cells transduced with chimeric antigen receptors (CAR-T) for solid tumors have not shown the
success observed for leukemia and lymphoma. To combat the effect of oxidative stress on tumor-specific T
cells, we have developed a novel approach to CAR-T protection by incorporating the damage suppressor
(Dsup) gene from an “extremotolerant” organism, the tardigrade. Tardigrades show extreme oxidative stress
resistance to alleviate cellular damage during desiccation. Therefore, we hypothesize that transgenic
expression of tardigrade oxidative stress response proteins in CAR-T will enhance their survival and
function in solid tumors and will mitigate effects of stress on the antitumor response.
Methods and Results: To this end, we have generated CAR-T expressing tardigrade oxidative stress
response gene Dsup to explore their functionality in solid tumor environments. To determine if Dsup
enhanced T cell survival under metabolic stress, we transduced primary T cells with tardigrade stress
response gene Dsup or a vector only control. When cultured with H2O2 to generate oxidative stress, T cells
transduced with Dsup have greater viability than T cells receiving only the control vector. To determine if
the expression of Dsup affected the antitumor efficacy of CAR T, we cocultured HER2 CAR-T with and
without Dsup for 48 hours with HER2-expressing FaDu tumor cells, then quantified tumor cell death by
flow cytometry. In preliminary data, we observed HER2-specific CAR-T with Dsup to kill tumor cells in
culture. To determine if Dsup improves the ability of CAR-T to target or kill cells in vivo, CAR-T
transduced with antioxidant gene Dsup were used to treat FaDu tumors grown in the chick chorioallantoic
membrane model. After treatment with Dsup-HER2.CAR-T, tumors were harvested for analysis, at which
time T cell infiltrates were seen throughout the tumor in 3D reconstructions generated by confocal
microscopy.
Conclusion: Together, these findings suggest that antioxidant genes have potential to enhance CAR-T
efficacy in solid tumors through oxidative stress protection.
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Discovery of glucocorticoid receptor degrading PROTACs as therapeutics for advanced prostate
cancer
Nicholas Blazanin1, James T. Link2, Robert A. Mullinax2, Ningping Feng2, Joseph Marszalek2, Jason Gay2,
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Background: Advanced castration-resistant prostate cancer (CRPC) is a devastating disease with
significant mortality. Inhibition of the androgen receptor with small molecule antagonists such as
enzalutamide has become a standard-of-care treatment option for prostate cancer. Unfortunately, most
patients invariably develop anti-androgen resistance. Signaling through the glucocorticoid receptor (GR) has
emerged as a primary mechanism of resistance to anti-androgen therapies, making it an attractive
therapeutic target. However, existing small molecule antagonists of GR suffer from partial agonist activity,
which limits their antitumor efficacy. To overcome this problem, we have developed bifunctional small
molecules known as proteolysis targeting chimeras (PROTACs) that induce potent degradation of GR.
Methods: Degrading capabilities and detailed assessment of one of our most potent PROTACs, GR-9059,
was analyzed in several human prostate cancer models. Bioavailability and tolerability of GR-9059 was also
examined in mice, and efficacy in combination with the anti-androgen enzalutamide was determined in a
clinically relevant prostate cancer tumor model in vivo.
Results: Several novel GR-degrading PROTACs were developed by linking a non-covalent inhibitor of GR
(RU-486) to pomalidomide, a ligand to the E3 ligase cereblon. Further study found one of these molecules,
GR-9059, to be selective and highly potent at reducing GR levels in CRPC prostate cancer cell lines,
regardless of AR expression status. Moreover, GR-9059 was 100-fold superior to the GR antagonist RU-486
in inhibiting cell growth of enzalutamide-resistant CRPC cell lines. Furthermore, pharmacokinetics and
pharmacodynamics (PD) studies in mice showed that GR-9059 was readily bioavailable and well tolerated
without any overt toxicities. Importantly, GR-9059 had synergistic anti-tumor efficacy in combination with
enzalutamide in a mouse xenograft model of CRPC. Finally, transcriptomic analysis of cells and xenograft
tumors revealed that the combination of GR-9059 and enzalutamide was associated with downregulation of
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key developmental pathways, including Hedgehog and Notch, that are frequently activated during therapy
resistance and tumor dormancy.
Conclusions: PROTAC-mediated degradation of GR is a highly powerful approach compared to currently
available GR antagonists and supports the notion that targeting GR combined with anti-androgens such as
enzalutamide may further improve prostate cancer management and survival.
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Autologous breast reconstruction results in better outcomes than implant-based reconstruction in
previously irradiated patients who require implant explantation due to infection
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Background: Breast implant explantation is often necessary to treat surgical site infections following
implant-based breast reconstruction (IBR). History of radiotherapy further complicates the reconstructive
choice. While some plastic surgeons perform autologous reconstruction following failed IBR due to
infection, others argue that a second IBR attempt is acceptable. There is no consensus regarding the optimal
reconstructive approach for patients with a history of radiotherapy and failed IBR due to infection.
Methods: We conducted a retrospective review of all consecutive patients with a history of radiotherapy
who underwent a second reconstructive attempt following IBR and implant explantation due to infection
between 2007 and 2019. The primary outcome measure was reconstruction failure (defined as flap loss in
the autologous group and a second implant explantation in the IBR group). Secondary outcome measures
included overall complications defined as complications at the recipient or donor sites and major
complications defined as any recipient or donor site complications requiring reoperation.
Results: We identified a total of 53 patients with a history of radiotherapy who underwent breast
reconstruction following IBR explantation due to infection; 27 (51%) received a subsequent autologous free
tissue transfer (FF), and 26 (49%) underwent a second IBR +/- a latissimus dorsi (LD) pedicled flap. No
significant differences in overall complications (33% vs. 42%, p=0.5), major complications (30% vs. 31%,
p=0.9), or breast-related complications (19% vs. 38%, p=0.1) were identified between the FF and IBR
groups, respectively. The FF group had a much lower rate of reconstruction failure compared to the IBR
group (7% vs. 31%, respectively, p=0.04). In the IBR group, 65% had LD flap in combination with IBR.
Reconstructive failure was lower in the LD+IBR group (24%) compared to the IBR-only group (44%);
however, this difference was not statistically significant (p=0.38)
Conclusion: Breast reconstruction can be safely performed in women with a history of radiotherapy and
implant explantation due to infection. IBR and FF patients had similar rates of overall and major
complications. However, reconstructive failure was significantly lower (over 4-fold) in the FF group and
potentially higher if IBR was performed without an LD flap. To reduce the risk of reconstructive failure,
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plastic surgeons should strongly consider autologous reconstruction in this patient population. When IBR is
necessary, the addition of an LD flap may improve reconstructive success.
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Autologous versus implant-based breast reconstruction in patients with history of breast-conserving
surgery and radiotherapy
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Background: Post-mastectomy radiotherapy is a known predictor of complications following breast
reconstruction. However, for women who undergo completion mastectomy after initial breast-conserving
therapy (BCT), the literature on the impact of previous radiation on reconstructive outcomes is scarce. The
goal of this study was to compare the outcomes of autologous vs. implant-based reconstruction (IBR) in
patients with a prior history of BCT undergoing subsequent mastectomy.
Methods: We conducted a retrospective review of all consecutive patients with a history BCT who
underwent subsequent mastectomy and ipsilateral breast reconstruction. Inclusion criteria included patients
who underwent reconstruction with a free flap (FF) or IBR (tissue expander/implant with or without a
latissimus dorsi flap). Overall complications were defined as complications at the recipient or donor sites at
any time after surgery while major complications were defined as any recipient or donor site complications
requiring reoperation.
Results: A total of 111 breast reconstructions were identified (49% FF, 51% IBR). Mean age was similar
between the two groups (52±8 vs. 51±9 years, p=0.5), but mean BMI was slightly higher in the FF group
(29±5 vs. 28±6, p=0.007). Hypertension was more common in the FF group (48% vs. 23%, p=0.005), while
other comorbidities including diabetes, smoking, and coronary artery disease were similar between the two
groups. Follow-up was longer in the FF group (88±50 months vs. 59±51, p=0.002). Reconstruction occurred
after a mean of 5±5 years (FF) and 6±5 years (IBR) from the receipt of radiation, p=0.4. No differences in
overall complications (59% vs. 51%, p=0.38) and major complications (26% vs. 32%, p=0.51) were
identified between FF and IBR. The FF group had a lower rate of major breast-related complications (11%
vs. 30%, p=0.015), while overall breast-related complications were similar between the two groups (43% vs.
47%, p=0.6). The FF group had a higher mean number of revision surgeries (1.3±1 vs. 0.4±0.7, p<0.0001).
Conclusion: Overall surgical-site complications were similar following FF or IBR in patients with a history
of BCT who subsequently underwent completion mastectomy. However, FF patients had lower risk of
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major breast complications and higher likelihood of revision surgery following reconstruction. These
findings might be important for surgeons to consider when counselling patients in this population on breast
reconstructive options.
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Does biologic mesh type impact outcomes in complex abdominal wall reconstruction?
Malke Asaad, Donald Baumann, Sahil Kapur, Alexander Mericli, David Adelman, Jun Liu, Charles E.
Butler
Department of Plastic & Reconstructive Surgery, The University of Texas MD Anderson Cancer Center,
Houston, TX.
Background: With the increased use of acellular dermal matrix (ADM) in abdominal wall reconstruction
(AWR), numerous types of ADM-based biologic meshes are now available. However, there is a paucity in
the literature regarding the differences in outcomes among these ADM types.
Methods: We conducted a retrospective analysis of all patients who underwent AWR using the two most
common types of ADM (porcine [Strattice] and bovine [Surgimend]) from 2005 to 2019. The primary
outcome measure was hernia recurrence, while surgical site occurrence (SSO) and surgical site infection
(SSI) were secondary outcome measures. We excluded patients with human ADM and less than 6 months of
follow-up. The cumulative hernia recurrence was estimated using Kaplan-Meier analysis.
Results: We identified 359 patients (49.5%) with porcine ADM and 366 (50.5%) with bovine ADM. There
was no difference in age (60±12 vs. 59±11 years in the porcine and bovine groups, respectively, p=0.36) or
body mass index (31±7 vs. 32±7 kg/m2, respectively, p=0.11) between the two groups. Median follow-up
was 34 months (range, 6-139 months). Cumulative hernia recurrence at 5 years was similar between the
groups (18% vs. 16% in the porcine and bovine groups, respectively, p=0.83). Rates of SSO (27% vs.
26.5%, p=0.88) and SSI (14% vs. 11%, p=0.22) were also similar.
Conclusion: Porcine and bovine ADM have similar hernia recurrence, SSO, and SSI rates for patients
undergoing AWR. Surgeons can choose either xenograft mesh with confidence as 5-year recurrence
outcomes rival those of synthetic mesh.
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Financial toxicity and contralateral prophylactic mastectomy – a propensity-score matched study
Malke Asaad1; Stefanos Boukovalas1; Carrie K. Chu1; Yu-Li Lin2; Cristina M. Checka3; Mark W.
Clemens1; Rachel A. Greenup4; Anaeze C. Offodile II1,2,5
1

Department of Plastic & Reconstructive Surgery, The University of Texas MD Anderson Cancer Center,

Houston, TX; 2Department of Health Services Research, The University of Texas MD Anderson Cancer
Center, Houston, TX; 3Department of Breast Surgical Oncology, The University of Texas MD Anderson
Cancer Center, Houston, TX; 4Department of Surgical Oncology, Duke University School of Medicine,
Durham, NC; 5Baker Institute for Public Policy, Rice University, Houston, TX.
Background: Contralateral prophylactic mastectomy (CPM) is increasingly performed in average-risk
patients despite the lack of survival benefit. In an era of heightened awareness of cancer treatment costs, we
sought to determine the impact of CPM on financial toxicity in breast cancer.
Methods: We conducted a cross-sectional study of female patients who underwent unilateral mastectomy
(UM) with or without CPM for breast cancer over an 18-month period at our institution (2018-2019). We
excluded patients with a history of genetic predisposition or bilateral cancer. Propensity-matching was used
to create two balanced groups with respect to the likelihood of undergoing CPM. The validated
Comprehensive Score for financial Toxicity (COST) evaluated financial toxicity among participants.
Multivariable regression analysis evaluated the relationship between CPM and financial toxicity. Relevant
domains of the Breast-Q and SF-12 instruments were also examined.
Results: Overall, 104 patients were identified, equally distributed across UM and CPM. CPM was not
associated with financial toxicity, as evidenced by comparable COST scores (adjusted difference, 1.53 [3.24 to 6.29]). Minor complications were significantly lower in UM patients (UM,8%; CPM, 31%). CPM
was associated with a significantly higher Breast-Q psychosocial well-being score (adjusted difference:
10.58 [1.34 to 19.83]). BREAST-Q surgeon satisfaction and SF-12 mental and physical component scores
were all noted to be similar.
Conclusions: Choice for CPM was associated with a higher percentage of minor complications but led to
improved psychosocial well-being without a higher degree of patient-reported financial toxicity in our
cohort. Prospective studies are needed to discern the influence of CPM on the incidence and trajectory of
financial toxicity.
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Self-reported risk factors for financial distress and attitudes regarding costs discussions in cancer
care – a single-institution cross-sectional pilot study of breast reconstruction recipients
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Background: High treatment costs associated with breast cancer are a substantial burden to patients and
society. Despite mounting awareness, patient perspectives about the value of cost discussions in breast
reconstruction (BR) and risk factors for financial distress are unknown.
Methods: We conducted a single-institution, cross-sectional survey of all women who underwent BR
following mastectomy or lumpectomy for breast cancer or risk reduction. Questions were derived from
previously published survey items, and we leveraged regression analysis to identify patient-level risk factors
for major financial distress.
Results: Of 2,293 patients, 647 returned the survey questionnaires (28.2% response rate). Of the 647
respondents, 399 (62%) underwent BR, and of these 35% (n=140) reported that total treatment expenses
were higher than expected and 32% (n=129) paid over $5000 in out-of-pocket costs (OOC). Furthermore,
71% (n=284) felt that surgeons should explain the estimated OOC when choosing a type of BR, and 51%
(n=205) believed that a financial consultation should be scheduled with every new cancer diagnosis.
However, only 13% (n=52) of patients reported having had cost discussions with the treatment team. The
incidence of major financial distress was 18% (n=70), and regression analysis showed that higher credit
score and annual income were associated with a 66% and 69% risk reduction, respectively.
Conclusion: Recipients of BR demonstrate unanticipated and unplanned financial strain related to out-ofpocket expenses and believe that cost-consciousness should impact treatment decisions. Lower income and
credit score are associated with financial distress. Cost discussions may optimize decision making in
preference-sensitive conditions.
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Introduction: Bcl-2 inhibitor venetoclax (VEN)-based regimen is a promising therapeutic option in AML,
especially for older and unfit patients. Although a high CR rate can be achieved rapidly, the duration of
response is limited, and most patients experience relapse within a few months. Considerable effort has been
made to investigate the mechanism of resistance to VEN in AML, but the data generated were mainly based
on findings in in vitro cell lines.
Methods and Results: To investigate the microenvironmental contribution to VEN resistance, we
performed experiments in vitro co-culturing primary patient samples with mesenchymal stromal cells
(MSCs) and in vivo using patient-derived xenograft models (PDX). We found that, without MSC co-culture,
VEN in general effectively induced apoptosis in both relapsed/refractory and treatment-naive samples.
However, such effect was significantly blunted in relapsed/refractory samples when co-cultured with MSCs,
suggesting a role of the microenvironment in mediating resistance to VEN. We treated a PDX model,
established from a patient who clinically relapsed after VEN/hypomethylating agent treatment, with the
Mcl-1 inhibitor AZD5991 alone and in combination with VEN. Although the combination significantly
prolonged survival (Carter B. et al, ASH 2018), the mice eventually died of the disease. By combining RNA
sequencing and targeted gene sequencing in samples from moribund PDX mice, we found neither
upregulation of reported targets that may mediate resistance in cell line screenings nor mutation of BCL2.
Instead, we observed that VEN treatment significantly induced a proinflammatory cytokine profile, which
includes colony-stimulating factor 1 (CSF1), CSF2, IL1, and IL4. This aberrant expression was even more
pronounced in samples from AML that relapsed from the VEN/AZD5991 combination group. Since primary
AML cells and macrophages/monocytes in niche possess receptors for these cytokines, our results suggest
that AML cells survive apoptogenic stress by a crosstalk involving specific cytokines. In addition,
expansion of monocytic subgroups in AML samples was reported to establish VEN resistance. We found
that AZD5991 significantly decreased monocytic cell markers, suggesting that Mcl-1 inhibition may
effectively eliminate monocytic cells in VEN- resistant/relapsed AML.
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Conclusions: We, here, identify a novel mechanism underlying VEN/Mcl-1 inhibitor resistance and are
investigating whether targeting aberrantly expressed cytokines such as CSF1 may overcome it.
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Background: Rotavirus is the leading cause of severe childhood gastroenteritis, with 128,500 deaths and
258 million cases worldwide. It is highly prevalent and infects almost every child by 5 years of age. Many
live, attenuated oral vaccines have been introduced; however, they are not equally efficacious worldwide. In
high-income countries, such as those in the Americas, Europe, and Asia, the vaccine efficacy is
approximately 90%. However, in low-income countries, such as those in Africa and South Asia, the efficacy
is much lower, approximately 50%-70%. One factor contributing to the reduced efficacy of rotavirus
vaccines in these countries is the coadministration of the live, oral poliovirus vaccine. Consistently,
coadministration of the two vaccines has been associated with reduced immunogenicity of rotavirus
vaccines.
Methods: To understand how poliovirus vaccines interfere with the rotavirus vaccine response, we utilized
human intestinal enteroids (HIEs), a non-transformed, physiologically active model of the human intestinal
epithelium. We infected HIEs with the oral poliovirus vaccine, Sabin type 1, and the oral rotavirus vaccine,
Rotarix, and assessed the effect of coinfection on vaccine infectivity and replication.
Results: Compared to single infections, coinfections resulted in decreased rotavirus replication, while
poliovirus replication remained unchanged, suggesting that the reduced response to rotavirus vaccines seen
in children may be due to poor replication of this vaccine when poliovirus vaccines are coadministered.
Immunofluorescent staining revealed that rotavirus and poliovirus do not infect the same cell. Time-course
studies showed that poliovirus replicated more rapidly than rotavirus. Therefore, coadministration of the two
vaccines likely favors poliovirus replication and infection over rotavirus; this effect can be remediated by
infecting with rotavirus prior to poliovirus.
Conclusions: Our model system recapitulates the inhibitory effect of poliovirus on rotavirus replication, and
we are beginning to understand contributing mechanisms. Understanding the mechanisms of interference
between rotavirus and poliovirus vaccines will provide evidence to support vaccine dosage or schedule
improvements to enhance vaccine efficacy.
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Background: Previous research has identified two groups of smokers: individuals with increased brain
reactivity to drug cues compared to non-drug rewards and individuals with the opposite brain reactivity
pattern. Here, to learn whether there are similar groups defined by brain reactivity patterns in other drugs
of abuse, we tested a sample of individuals with cocaine use disorder (CUD). We also tested if the two
groups of cocaine users display behavioral differences in response to cues.
Methods: Individuals with CUD (n = 43) completed a picture viewing task while we recorded their
electroencephalogram. Image categories included pleasant (erotic, romantic, and sweet foods),
unpleasant (mutilations, violence, and accidents), cocaine, and neutral images. Brain reactivity was
measured as the amplitude of the late positive potential (LPP) over the centro-parietal electrodes from
400-800 ms after picture onset. Participants also completed an eye-tracking task that measured antisaccade error rates in response to neutral and cocaine cues. Cluster analysis identified groups of
participants based on their LPP amplitude. Independent samples t-test identified group differences in
error rates on the eye-tracking task.
Results: The cluster analysis revealed two groups of cocaine users similar to previous research on
smokers. One group had increased brain reactivity to pleasant compared with cocaine images, while the
other had increased brain reactivity to cocaine compared with pleasant images. The second group
(cocaine > pleasant) also had higher attentional bias, as measured by increased anti-saccade error rates
on drug trials compared with neutral trials, compared with the first group (pleasant > cocaine).
Conclusions: This is the first study to demonstrate two groups of cocaine users defined by brain
reactivity patterns. The two groups also differed behaviorally, with the second group (cocaine >
pleasant) having a more difficult time disengaging their attention toward drug stimuli. These results
suggest that these brain reactivity patterns may cut across addiction populations and provide important
information about how the groups may have different behavioral consequences. Future directions
include determining if the brain reactivity patterns can be useful in the personalization of treatment.
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Background: Despite effective treatment, no curative therapy is currently available for metastatic
prostate cancer. The mechanisms of progression are diverse and include fibroblast growth factor (FGF)
axis activation, underpinning the importance of developing FGF receptor (FGFR) blockade as therapy
for advanced prostate cancer.
Methods: We performed in vivo preclinical approaches and immunohistochemical studies in human
samples. To understand the mechanism of FGFR1-induced metastases, we performed RPPA of PC3
cells stably expressing FGFR1 isoforms and analyzed by applying Ingenuity Pathway Analysis.
Results: We found that FGFR1 expression in prostate cancer cells significantly reduced mouse survival
and increased the incidence of bone metastases. Accordingly, castration-resistant human prostate cancer
bone metastases samples revealed a significant enrichment of FGFR1 expression compared with
treatment-naïve, non-metastatic primary tumors. Our studies also showed that FGFR1 induced
expression of the relatively uncharacterized anchoring filament protein ladinin 1 (LAD1) in PC3 cells.
Furthermore, LAD1 expression was significantly enriched in castration-resistant human prostate cancer
bone metastases, supporting the concept that LAD1 mediates, at least in part, the prostate cancer
metastatic phenotype.
Conclusions: Our studies indicate that new FGFR1 signatures define pathway activation, and this
knowledge will help identify markers of pathway inhibition in human prostate cancer. Our findings also
show that FGFR1 underlies the metastatic dissemination of prostate cancer and implicate, for the first
time, LAD1 in the metastatic phenotype of a subpopulation of men with prostate cancer and as a target
of FGFR1 signaling. Hence, the biological implications of LAD1 expression in prostate cancer
pathogenesis warrant further investigation. Since FGFR1 is a major factor involved in disease
progression under treatment, the implication of the FGFR1-LAD1 axis in prostate cancer metastatic
progression provides a framework of new opportunities for development of FGFR1-LAD1 targeted
therapies and/or the identification of markers of progression.
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Background: The high relapse rate of T-ALL is associated with persistence of chemoresistant cells,
harboring activating NOTCH1 gene mutations. Since Notch1-directed therapies showed limited
responses, targeting key oncogenic and metabolic pathways downstream of NOTCH1 may offer novel
approaches. We demonstrated that transformation of thymocytes into preleukemic stem cells (pre-LSC)
requires elevated Notch1 upon the presence of Scl/Lmo1; and that survival of NOTCH1-mutated TALLs depends on OxPhos. OxPhos inhibition (OxPhos-i) using the complex I inhibitor IACS-010759
reduces tumor burden in NOTCH1-mutated T-ALL PDX models. Thus, we hypothesized that
chemotherapy (Vincristine, Dexamethasone, L-Asparaginase, VXL) aided by OxPhos-i overcomes
chemoresistance, depletes LSCs, and combats T-ALL.
Methods: We utilized comprehensive molecular and functional assays: viability, apoptosis, niche-based
assay, GSEA of pre-LSCs, NetBid, Seahorse, targeted and untargeted metabolomics, and mass
cytometry. The study was conducted on pre-leukemic and leukemic murine models of human Notch1 TALL harboring specific genotypes: LMO1, SCL-LMO1, NOTCH1, LMO1-NOTCH1, and SCL-LMO1NOTCH1; human T-ALL cell lines (n=9); patient samples (n=5); and PDX models (n=3).
Results: We identified co-occurrence of increased expression of Notch 1 target genes and OxPhos as a
highest-ranked gene set at the preleukemic stage (GSEA). In pre-LSC, OxPhos-i reduced viability upon
activation of Notch1 by its ligand DL4. Without DL4 activation—among thymocytes harboring LMO1,
SCL-LMO1, NOTCH1, LMO1-NOTCH1 and SCL-LMO1-NOTCH1 genotypes—only those with the
Notch1 oncogene responded to OxPhos-i. At the leukemic stage, in SCL-LMO1-induced murine T-ALL,
only oncogenic Notch1 elevated OxPhos pathway. The same pattern of co-segregation of NOTCH1
mutations with significant downregulation of apoptosis signaling and upregulation of OxPhos genes
occurred in the T-ALL COG patient cohort (n=263, TARGET) prior to chemotherapy. VXL
chemotherapy combined with OxPhos-i triggered a metabolic shut-down indicated by reduced OCR and
ECAR (Seahorse) with profound reduction of viability (CTG, flow cytometry) in vitro. This resulted in
metabolic changes and induction of apoptosis in leukemic cells in vivo, demonstrated by Metabolomics,
RNAseq, and CyTOF analyses. Finally, VXL-OxPhos-i resulted in reduced leukemia burden and
extension of overall survival in three aggressive T-ALL PDX models (p<0.0001).
Conclusions: In T-ALL, OxPhos upregulation occurs upon activation of NOTCH1 signaling. Activation
of Notch1 sensitizes pre-LSCs and LSCs to OxPhos-i. Targeting OxPhos in combination with
chemotherapy facilitates eradication of chemoresistant NOTCH1-driven T-ALL through direct targeting
of the key metabolic regulators of OxPhos conferred by mutant NOTCH1 in T-ALL. Clinical trials
rewiring metabolism by incorporation of OxPhos-i to standard-of-care therapy in patients with
NOTCH1-mutated T-ALL are warranted to improve patients’ outcomes.
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Background: Enhanced recovery after surgery (ERAS) pathway is a multidiscipline evidence-based
approach aimed at improving perioperative patient care and optimizing recovery following surgery. The
purpose of this study is to assess the impact of ERAS pathway on opioid use and patient outcomes
following microsurgical breast reconstruction (MSBR) at a high-volume center.
Methods: A retrospective cohort study was performed on patients who underwent MSBR from June
2018 to December 2018 for the conventional cohort (CC), and from August 2019 to December 2019 for
the ERAS cohort (ERAS). Primary outcome measures included morphine milligram equivalents (MME)
and 30-day complication rates. Secondary outcomes included length of hospital stay (LOS) and pain
scores.
Results: A total of 186 patients (CC, 108 [58%]; ERAS, 78 [42%]) underwent MSBR during the study
period. Similar age (p=0.64) and BMI (p=0.75) were identified in both groups. LOS was slightly shorter
in the ERAS group (4.6±1.1 vs. 4.9±0.9, p=0.01) while the complication rate was significantly higher in
the CC group (33% vs. 19%, p=0.03). Total MME consumption was significantly lower in the ERAS
cohort (18.3±11.2 vs. 32.4±26.8, p=0.001). Despite lower opioid use, average pain scores did not
significantly differ between ERAS and CC patients at any time point (2.3±1.4 vs 2.4±1.2, p=0.24).
Regarding the intraoperative anesthetic choice, volatile anesthesia was used in 105 patients (56%), total
intravenous anesthesia in 21 (11%), and combined anesthesia in 60 (32%) with no significant difference
between CC and ERAS. There were no differences in pain scores or MME use between the different
anesthesia types. In our multivariate model, ERAS was the only predictor of lower MME consumption.
Conclusions: The implementation of ERAS pathway for MSBR improves patient outcomes by reducing
length of stay, total opioid consumption, and incidence of postoperative complications. Type of
anesthesia does not seem to impact MME use or pain scores in MSBR patients.
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Background: 5-Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine
plus nanoparticle albumin-bound (nab)-paclitaxel (GA) are first-line chemotherapy regimens for
pancreatic cancer, but their relative efficacy in the setting of localized disease is unknown. The aim of
this study was to evaluate radiographic and serologic measures of response to first-line chemotherapy
with FOLFIRINOX or GA and to determine the associations between these drug regimens, putative
measures of response, and survival.
Methods: Consecutive patients who were diagnosed with previously untreated localized pancreatic
ductal adenocarcinoma at MD Anderson Cancer Center between January 1, 2010, and December 31,
2017, and who received at least 3 cycles of first-line chemotherapy with FOLFIRINOX or GA were
included. The main outcomes were resection rate, radiographic (RECIST 1.1 and change in tumor
volume or anatomic staging) and serologic (CA 19-9 level) metrics of response to first-line
chemotherapy, and overall survival.
Results: A total of 485 patients were treated with FOLFIRINOX (n = 285; 59%) or GA (n = 200; 41%)
as first-line chemotherapy. Patients treated with FOLFIRINOX were generally younger and had better
performance status but more invasive tumors than patients who received GA (P < .01 and P = .01,
respectively). After we conducted propensity score matching to control for these biases, many objective
serologic and radiographic metrics of response to FOLFIRINOX and GA—including low rates of local
tumor downstaging—did not differ. However, RECIST partial response was more common among
patients treated with FOLFIRINOX. Moreover, (chemo)radiation was more commonly administered to,
and pancreatectomy was subsequently performed more frequently for, patients initially treated with
FOLFIRINOX. The overall survival duration of patients treated with GA was similar to that of patients
treated with FOLFIRINOX (HR 1.48 [95% CI 0.97 – 2.26], P = 0.07).
Conclusions: In this cohort of patients with localized pancreatic adenocarcinoma who received
FOLFIRINOX or GA as their first line of therapy, FOLFIRINOX was associated with higher rates of
RECIST PR and subsequent pancreatectomy than GA, but the overall survival associated with these
regimens was similar.
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Background: Clinical outcomes of patients with Philadelphia chromosome (Ph)-positive B cell acute
lymphoblastic leukemia (B-ALL) have been significantly improved with the addition of tyrosine kinase
inhibitors (TKIs). Treatment with a TKI alone or a TKI with chemotherapy results in morphological
complete response in nearly all patients with Ph-positive B-ALL. However, persistence of measurable
residual disease (MRD) and disease relapse remain major clinical problems. Identification of predictive
and prognostic biomarkers for Ph-positive B-ALL is urgently needed. Recurring genetic abnormalities
such as deletions in IKZF1, CDKN2A/2B, PAX5, BTG1, and EBF1 have been identified in Ph-positive
B-ALL. Among those, IKZF1 deletion has been associated with poor prognosis in Ph-positive B-ALL
patients treated with imatinib-based or dasatinib-based regimens. However, molecular determinants for
clinical outcomes in patients treated with ponatinib (a potent TKI) are not known. Here, we have
systematically analyzed genetic alterations in adult Ph-positive B-ALL patients uniformly treated in
clinical trials with hyper-CVAD plus dasatinib or hyper-CVAD plus ponatinib regimens and
investigated the molecular determinants for treatment outcomes and prognosis.
Methods: We analyzed pretreatment bone marrow or peripheral blood specimens collected from adults
with Ph-positive B-ALL who participated in clinical trials with either hyper-CVAD plus dasatinib
(NCT00390793, N = 55) or hyper-CVAD plus ponatinib (NCT01424982, N = 50). Targeted capture

DNA sequencing of 295 genes (N = 102) or whole exome sequencing (WES, N = 3) was performed.
Genome-wide copy number analysis (CNA) was performed using either SNP microarray (N = 102) or
WES (N = 3).
Results: The most frequently detected alterations were IKZF1 deletion. Among the 63 patients with
IKZF1 deletion, we addressed detailed deletion site in 53 cases. Ik6 subtype, which is characterized by
deletion of exons 4-7 (N = 28, 23 %) was most frequently detected followed by Ik2 subtype, which
involves deletion of exon 2 (N = 20, 32 %). Patients harboring Ik2 subtype deletion or Ik6 subtype
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deletion showed significantly worse event-free survival (EFS) (hazard ratio [HR] = 1.91; p = 0.048) and
overall survival (OS) (HR = 2.36; p = 0.019) than patients without IKZF1 deletion or those
with IKZF1 deletion other than the Ik2 or Ik6 subtypes. We defined the IKZF1plus group as the group
consisting of the patients with deletion of IKZF1 and other deletions. Then, we performed univariate
analysis for patients with IKZF1 deletion in order to find the significant deletion partner
of IKZF1 deletion in terms of prognosis, and we defined the IKZF1plus(rev) group as patients
with IKZF1 deletion and both CDKN2A/2B deletions and VPREB1 deletion, or at least one of them.
The IKZF1plus(rev) group showed worse prognosis on EFS and OS than the non-IKZF1plus(rev) group.
Combining the results of the impact of Ik subtype and IKZF1plus(rev) group on EFS and OS, we defined
an IKZF1-driven high-risk group as patients harboring either alteration of Ik2/Ik6 subtype
or IKZF1plus(rev). The IKZF1-driven high-risk group showed worse prognosis on EFS and OS than the
IKZF1-driven low-risk group. Next, we performed univariate and multivariate analyses combining
baseline features, TKI type, and MRD status to assess their impact on outcome. Multivariate analysis
showed that TKI type, MRD status at 3 months, and IKZF1-driven high-risk group were independent
factors for OS. In patients treated with hyper-CVAD plus ponatinib and categorized into IKZF1-driven
low-risk group, the 5-year EFS and OS rates were 92.0% and 96.0%, respectively.
Conclusion: In this study, unlike with dasatinib-based therapy, we demonstrated that an IKZF1-driven
high-risk group was associated with worse EFS and OS than IKZF1-driven low-risk in the context of
hyper-CVAD plus ponatinib. Evaluation of the prognostic implication of using IKZF1-driven risk at the
time of the diagnosis may be useful to personalize treatment in order to improve the clinical outcomes of
patients with Ph-positive B-ALL in the era of ponatinib.
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Background: Sepsis remains one of the leading causes of death and currently has no therapy available
due to the lack of deep mechanistic understanding and of subject stratification by age, gender and
comorbidities in most preclinical and clinical trials. Here, we used diverse human samples and in vivo
models to define sepsis-associated micro (mi)RNAs that qualify as therapeutic targets.
Methods: To define deregulated miRNAs, we used peripheral blood mononuclear cells (PBMCs) from
sepsis patients, whole blood samples from sepsis survivors, and RNA-seq data from healthy individuals.
For confirmation of the therapeutic potential of the identified miRNAs, we used multiple animal models:
mouse cecum ligation-puncture (CLP)-induced sepsis, mouse viral microRNA challenge, and baboon
Gram-positive and Gram-negative sepsis models. We tested the therapeutic potential of sepsis-miRNAs
in CLP-induced sepsis in mice of different ages, analyzing survival and, for mechanistic insight, the
peripheral immune response. Furthermore, we used an in vitro miRNA knockout model to define the
exact molecular targets of sepsis-miRNAs using Ago2-immunoprecipitation.
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Results: Based on expression is serial human sepsis samples and confirmed data from in vivo models,
miR-93-5p passed the selection criteria as a potential therapeutic target. MiR-93-5p was significantly
overexpressed in plasma and PBMCs from baboons that died early after induction of Gram-positive and
Gram-negative sepsis and was downregulated in humans who experienced long-term survival after
sepsis diagnosis. Therapeutically, inhibiting miR-93-5p prolonged the overall survival of CLP-induced
sepsis in mice, and the effect was stronger in older mice. Targeting miR-93-5p in sepsis reduced the
frequency of inflammatory monocytes and increased the frequency of circulating CD4+ and CD8+
effector memory T cells. On the molecular level, miR-93 affected multiple pro- and anti-inflammatory
pathways, in accordance with the changes in cell frequencies that we observed.
Conclusions: MiR-93-5p is a potential therapeutic target in sepsis in elderly patients because it affects
both innate and adaptive immunity.

74

